Biomarker-Based Immunoassays Market Report 2026

The biomarker-based immunoassays market size has grown rapidly in recent years. It will grow from $6.6 billion in 2025 to $7.37 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases driving demand for early diagnostic testing, growing use of enzyme linked immunosorbent assay in clinical laboratories, expansion of hospital diagnostic infrastructure and laboratory networks, rising adoption of antibody based detection techniques in research applications, development of standardized biomarker identification methods in biomedical research.

The biomarker-based immunoassays market size is expected to see rapid growth in the next few years. It will grow to $11.55 billion by 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to rising demand for personalized medicine and precision diagnostics, increasing integration of ai and machine learning in biomarker analysis, growing adoption of multiplex and high throughput immunoassay technologies, expansion of point of care diagnostic testing in remote healthcare settings, increasing investment in pharmaceutical research and drug discovery applications. Major trends in the forecast period include ai driven biomarker interpretation and predictive disease modeling for enhanced diagnostic accuracy, multiplex immunoassay platforms enabling simultaneous detection of multiple biomarkers, cloud integrated immunoassay systems for centralized diagnostic data management, lab automation and robotic sample processing for high throughput immunoassay testing, next generation point of care immunoassay devices for rapid clinical diagnostics.

The increasing incidence of oncology cases is expected to propel the growth of the biomarker-based immunoassays market going forward. Oncology cases refer to the occurrence of cancers caused by abnormal and uncontrolled cell growth that can spread to different parts of the body. The rising incidence of oncology cases is driven primarily by aging populations, as the risk of developing cancer increases significantly with age and longer life expectancy leads to a higher number of diagnosed cases. Biomarker-based immunoassays support the management of oncology cases by enabling early detection, precise monitoring of disease progression, and guiding personalized treatment decisions through accurate identification of cancer-specific biomarkers. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are projected in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing incidence of oncology cases is contributing to and propelling the growth of the biomarker-based immunoassays market.

Leading companies operating in the biomarker-based immunoassays market are focusing on developing innovative solutions such as ultrasensitive immunoassay platforms to enable early and accurate detection of low-abundance biomarkers. Ultrasensitive immunoassay platforms are advanced diagnostic systems designed to detect extremely low concentrations of biomarkers with high precision and specificity, helping enable earlier disease detection, improved diagnostic accuracy, and better monitoring of disease progression compared to conventional assays. For example, in July 2025, Spear Bio Inc., a US-based biotechnology company, launched SPEAR UltraDetect, a next-generation ultrasensitive immunoassay solution designed to enhance biomarker detection in neurodegenerative disease research. The platform utilizes proprietary homogeneous assay technology that eliminates the need for wash steps, unlike traditional heterogeneous immunoassays, enabling faster and more streamlined workflows. It is capable of detecting protein biomarkers at attomolar concentrations using as little as 1 µL of sample, significantly improving sensitivity and efficiency. The solution includes assays targeting key neurological biomarkers such as pTau217, pTau231, GFAP, and NfL, supporting early and accurate disease analysis.

In July 2025, Alden Scientific Inc., a US-based healthcare technology company, acquired Oncimmune Germany GmbH for an undisclosed amount. With this acquisition, Alden Scientific Inc. aims to improve its multi-omic and precision medicine capabilities by integrating advanced immunodiagnostics and biomarker discovery technologies, thereby strengthening its ability to study immune-mediated diseases and expand its data-driven health platform. Oncimmune Germany GmbH is a Germany-based healthcare technology company specializing in immunodiagnostics and autoantibody biomarker discovery services through its proprietary platforms.

Major companies operating in the biomarker-based immunoassays market are Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Eurofins Scientific SE, Bio-Rad Laboratories Inc., QIAGEN N. V., Tecan Trading AG, Autobio Diagnostics Co. Ltd., Promega Corporation, Sekisui Diagnostics LLC, Boditech Med Inc., Dynex Technologies Inc., NanoEntek Inc., J. Mitra & Co. Pvt. Ltd., ALPCO Diagnostics LLC, Micropoint Bioscience Inc., Coris BioConcept, MiCo BioMed Co. Ltd., Abionic SA, ANP Technologies Inc., Axela Inc., Epitope Diagnostics Inc., MedMira Inc., Nanomix Inc.

North America was the largest region in the biomarker-based immunoassays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarker-based immunoassays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biomarker-based immunoassays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biomarker-based immunoassays market consists of sales of rapid test kits, chemiluminescent immunoassay kits, multiplex assay kits, antibodies, reagents, lateral flow readers, and flow cytometers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.